Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for PURE Bioscience (PURE : OTC)

• Company Description    PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including methicillin-resistant Staphylococcus aureus (MRSA), or staph infection. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of `green` products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. Number of Employees: 12

• Price / Volume Information    Yesterday's Closing Price: $0.08 Daily Weekly Monthly 20 Day Moving Average: 14,021 shares Shares Outstanding: 111.89 (millions) Market Capitalization: $8.39 (millions) Beta: 0.31 52 Week High: $0.16 52 Week Low: $0.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -25.00% -27.75% 12 Week 8.70% -12.62% Year To Date 17.56% 11.55%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 771 JAMACHA ROAD #512 - EL CAJON,CA 92019 USA ph: 619-596-8600 fax: 619-596-8790 melliott@purebio.com http://www.purebio.com

• General Corporate Information    Officers Robert Bartlett - President; Chief Executive Officer Ivan Chen - Chairman of the Board Mark Elliott - Vice President; Finance;Principal Financial and Ac Tom Myers - Director David Rendall - Director Peer Information PURE Bioscience (BJCT) PURE Bioscience (CADMQ) PURE Bioscience (APNO) PURE Bioscience (UPDC) PURE Bioscience (IMTIQ) PURE Bioscience (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 74621T209 SIC: 2890 Fiscal Year Fiscal Year End: July Last Reported Quarter: 04/01/25 Next Expected EPS Date: 11/04/25 Share - Related Items Shares Outstanding: 111.89 Most Recent Split Date: 8.00 (0.13:1) Beta: 0.31 Market Capitalization: $8.39 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 4.39 EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: 11.34% vs. Previous Quarter: 25.58% ROE 04/30/25 - - 01/31/25 - - 10/31/24 - - ROA 04/30/25 - -334.78 01/31/25 - -383.19 10/31/24 - -352.61 Current Ratio 04/30/25 - 1.08 01/31/25 - 0.65 10/31/24 - 1.00 Quick Ratio 04/30/25 - 0.94 01/31/25 - 0.56 10/31/24 - 0.92 Operating Margin 04/30/25 - -147.72 01/31/25 - -166.58 10/31/24 - -183.96 Net Margin 04/30/25 - -147.72 01/31/25 - -166.58 10/31/24 - -183.96 Pre-Tax Margin 04/30/25 - -147.72 01/31/25 - -166.58 10/31/24 - -183.96 Book Value 04/30/25 - -0.04 01/31/25 - -0.04 10/31/24 - -0.03 Inventory Turnover 04/30/25 - 9.60 01/31/25 - 11.22 10/31/24 - 11.04 Debt-to-Equity 04/30/25 - - 01/31/25 - - 10/31/24 - - Debt-to-Capital 04/30/25 - - 01/31/25 - - 10/31/24 - -

Powered by Zacks Investment Research ©